Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Class |
|---|---|
| Bavarian Cancer Research Center (BZKF) | UNKNOWN |
| University Hospital Augsburg | OTHER |
| Ludwig-Maximilians - University of Munich | OTHER |
Not provided
Not provided
Not provided
Not provided
Analysis of peripheral immune cells before, during, and after brachytherapy treatment. Corresponding analysis of tissue samples collected during brachytherapy treatment.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Primary brachytherapy | Patients receiving sole primary brachytherapy (either LDR-BT or HDR-BT) for low or low intermediate risk prostate cancer | ||
| Salvage brachytherapy | Patients receiving sole brachytherapy (either PDR-BT or HDR-BT) for locally recurrent prostate cancer after prior irradiation with prostate in situ |
Not provided
| Measure | Description | Time Frame |
|---|---|---|
| Longitudinal changes of peripheral immune cells and cell-free DNA and tumor-associated tissue in patients with prostate cancer treated with brachytherapy | Longitudinal changes of peripheral immune cells and cell-free DNA and tumor-associated tissue in patients with prostate cancer treated with brachytherapy in the primary as well as in the recurrent setting. | Blood withdrawal pre-brachytherapy treatment, during surgery, one day after brachytherapy and at the first follow-up visit 4-12 weeks later. Tissue samples at every brachytherapy procedure. |
| Measure | Description | Time Frame |
|---|---|---|
| Treatment-related toxicity | Acute toxicity related to brachytherapy | Up to 6 months |
| recurrence-free survival | recurrence-free survival |
Not provided
Inclusion Criteria Arm 1:
Inclusion Criteria Arm 2:
Exclusion Criteria:
Not provided
Not provided
Not provided
Prostate cancer patients planning to undergo sole brachytherapy treatment
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Claudia Schweizer, MD | Contact | +49 9131 85 33968 | claudia.schweizer@uk-erlangen.de | |
| Anna-Jasmina Donaubauer, Dr. rer. nat. | Contact |
| Name | Affiliation | Role |
|---|---|---|
| Claudia Schweizer, MD | Strahlenklinik Universitätsklinikum Erlangen | Principal Investigator |
| Anna-Jasmina Donaubauer, Dr. rer. nat. | Strahlenklinik Universitätsklinikum Erlangen | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Klinik für Strahlentherapie | Not yet recruiting | Augsburg | Bavaria | 86156 | Germany |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
wohle blood, prostate tissue samples
| Up to 6 months |
| Overall survival | Overall survival | Up to 6 months |
| Strahlenklinik Erlangen | Recruiting | Erlangen | Bavaria | 91054 | Germany |
|
| Klinik und Poliklinik für Strahlentherapie und Radioonkologie | Not yet recruiting | Munich | Bavaria | 81377 | Germany |
|
| ID | Term |
|---|---|
| D011471 | Prostatic Neoplasms |
| D004194 | Disease |
| ID | Term |
|---|---|
| D005834 | Genital Neoplasms, Male |
| D014565 | Urogenital Neoplasms |
| D009371 | Neoplasms by Site |
| D009369 | Neoplasms |
| D005832 | Genital Diseases, Male |
| D000091662 | Genital Diseases |
| D000091642 | Urogenital Diseases |
| D011469 | Prostatic Diseases |
| D052801 | Male Urogenital Diseases |
| D010335 | Pathologic Processes |
| D013568 | Pathological Conditions, Signs and Symptoms |
Not provided
Not provided